For ACPE-Accredited CE Platforms
Elevating Healthcare, One CE at a Time

Clinically sharp
CE content —
ready to license.

We build it. You accredit it. Fully developed, ACPE-submission-ready interprofessional continuing education (CE) courses built by a licensed, practicing PharmD and CE content expert. You bring the accreditation — we bring the content.

250+ Contact Hours Available
135+ Fully Developed Courses
IPCE Activity Format
RN · LPN · NP · PA · MD · RPh · PharmD
★ Bundles 01 & 01b · 8 Courses · Regulatory + SUD
Compliance & Regulatory
13.0 CH Total RN · PharmD · NP · PA · MD IPCE
Law Credit Eligible
View Details
Get Pricing
★ Bundle 02 · 6 Courses · Core + Extended
GLP-1 Clinical Bundle
9.0 CH Total RN · PharmD · NP · PA · MD IPCE
View Details
Get Pricing
Custom CE Development
Have a topic your audience needs?
Any Topic Flat Fee Per Course Your ACPE #
Contact Us →
250+
Contact Hours
135+
Complete Courses
20
Curated Bundles
ACPE
Submission-Ready
Available Catalog

24 bundles. 250+ contact hours.

Complete course suites ready for licensing — slides, syllabi, assessments, peer review forms, and author documentation. 135+ fully developed courses across 24 specialty bundles.

Bundle 01 · Compliance
Compliance & Regulatory Bundle
5.0 Contact Hours RN · LPN · NP · PA · RPh · MD IPCE
Opioid Use Disorder & Pain Management — 2.0 CH
Pharmacy Law Update 2026 — 1.0 CH
CS Dispensing Law & DEA Compliance — 2.0 CH
Bundle 01b · Compliance
Compliance Bundle 2 — MATE Act & SUD
8.0 Contact Hours RN · LPN · NP · PA · RPh · MD IPCE
Neuroscience of Addiction: Moving Beyond Stigma — 2.0 CH
Opioid Overdose Prevention & Naloxone — 1.5 CH
Medications for Opioid Use Disorder — 2.0 CH
MATE Act & Buprenorphine Prescribing — 1.5 CH
Stimulant & Alcohol Use Disorders — 1.0 CH
Bundle 02 · Clinical · Core Tier
GLP-1 Clinical Bundle
4.0 Contact Hours RN · PharmD · NP · PA · MD IPCE
GLP-1 Receptor Agonists: Mechanisms, Agents & Clinical Use — 2.0 CH
Optimizing GLP-1 Therapy: Titration, Side Effects & Counseling — 1.0 CH
GLP-1 in Obesity Management — 1.0 CH
Bundle 02b · Clinical · Extended Tier
GLP-1 Extended Bundle
5.0 Contact Hours RN · PharmD · NP · PA · MD IPCE
Add-on to Core — license together or separately
CV & Renal Benefits of Incretin Mimetics — 2.0 CH
Managing Sarcopenia & Body Composition on GLP-1 Therapy — 1.5 CH
The PBM Perspective: Prior Auth & Formulary Tiers for Obesity — 1.5 CH
The eCEcredits Difference

Clinically sharp.
Submission-ready. Delivered fast.

135+ fully developed courses. 250+ contact hours. ACPE-submission-ready from day one — built by a licensed PharmD, delivered in days, white-labeled under your brand.

Built by a Licensed Clinician
Every course authored by a practicing PharmD/RPh. Clinical accuracy is built in from slide one — not added at peer review.
ACPE-Submission-Ready
Every course is built to ACPE Standards 2.0. Slides, syllabus, assessments, answer keys, peer review documentation, and learning objectives — everything ACPE requires in one package, under your provider number.
👥
True Interprofessional Format
IPCE-formatted for pharmacists, pharmacy technicians, nurses, NPs, PAs, and physicians — one course, every credential.
🏷️
Your Brand, Your ACPE Number
Delivered under your ACPE provider number and your brand. Your catalog, your identity — we stay behind the scenes.
Delivered in 5 Business Days
Signed agreement to full course file delivery in five business days. No development wait, no SOW delays — content is built and ready.
Flat-Fee, Predictable Pricing
Annual flat-fee licensing. No per-learner royalties, no usage caps — scalable whether you serve 500 learners or 500,000.
Who We Work With

CE content built for
all healthcare providers

Our IPCE-formatted courses are designed for the full interprofessional care team — any accredited CE organization serving Nurses, Pharmacists, Pharmacy Technicians, Nurse Practitioners, Physician Assistants, or Physicians can license our content.

Nursing CE Platforms Primary
ANCC-accredited nursing CE platforms serving RNs, LPNs, and APRNs — the largest CE audience. Our IPCE courses are ideal for cross-disciplinary nursing CE catalogs covering opioids, compliance, and GLP-1 agents.
👩‍⚕️
NP & PA CE Platforms Primary
AANP, ANCC, and AAPA-accredited platforms serving nurse practitioners and physician assistants. Clinical content — GLP-1, OUD, DEA compliance — is directly relevant to NP/PA prescribing practice.
Pharmacy CE Platforms Primary
ACPE-accredited platforms serving RPh, PharmD, and CPhT audiences. Compliance and GLP-1 bundles are high-demand catalog additions for any pharmacy CE provider.
Hospital & Health Systems
Academic medical centers and health systems with internal accreditation serving the full care team — nurses, pharmacists, physicians, NPs, and PAs — all in one organization.
Physician CME Platforms
ACCME-accredited CME providers serving MDs and DOs. GLP-1 clinical content and OUD/pain management are high-priority CME topics for prescribing physicians.
🏛️
Professional Associations
State and national nursing, pharmacy, and advanced practice associations offering CE/CME to their membership — ASHP, ANA, AANP, AAPA, and state chapters.
Built Right, Every Time

How every course gets built.

1
Step 01
Primary Source Research
Every course starts with FDA prescribing information, published clinical guidelines, and landmark trial data. No secondary summaries.
2
Step 02
Outcomes-Based Design
Learning objectives are written to ACPE Standards 2.0 with action verbs and measurable outcomes before a single slide is built.
3
Step 03
Clinical Accuracy Review
Every clinical claim is cited in speaker notes. Dosing, black box warnings, and guideline thresholds are verified against current primary sources before delivery.
4
Step 04
Peer Review
Every course undergoes clinical peer review by a licensed healthcare professional before licensing. Corrections applied before delivery.
Custom CE Development
Don't see the topic you need?
We build CE from scratch — any topic, any audience, full ACPE-ready package. Flat-fee per course. You accredit it under your own provider number.
→  Learn About Custom Development

Your CE catalog gap is
one call away from solved.

135+ courses. 250+ contact hours. ACPE Standards 2.0. White-labeled under your brand.

Schedule a Discovery Call Browse the Catalog
Course Catalog · 2026

250+ Contact Hours.
24 Bundles. 135+ Courses.

Every course is fully developed and submission-ready — PowerPoint slides, syllabus, pre/post-assessments with answer keys, and peer review documentation.

Free Sample Package
See the quality before you commit
Download the GLP-1 Clinical Bundle sample — monograph excerpt, slides, syllabus, and assessment questions included.
No account needed  ·  Instant delivery
What's Included With Every Course
PowerPoint Slides
Fully designed, branded slide deck with speaker notes. White-label version with logo placeholder zone available.
📄
Course Syllabus
ACPE-formatted syllabus with learning objectives, target audience, content outline, and CE designation.
Pre & Post Assessments
Full assessment sets with answer keys. Mapped to learning objectives and formatted for platform upload.
Peer Review Forms
Completed peer review documentation per ACPE standards, ready for your submission file.
👤
Author Documentation
Author CV, disclosure forms, and attestation documentation for your ACPE submission packet — provided for every course author.
🔄
Annual Updates
Content refresh included with annual licensing agreements to keep courses current with clinical guidelines.
Services

Ready-made.
Custom-built. Expert-advised.

Whether you need a ready-made catalog or a custom course built from scratch, we have a model that fits your organization.

Catalog Licensing
Ready-made. Submission-ready. Ship it fast.
License our existing course bundles and have fully developed CE content in your platform in days — not months. All materials needed for ACPE submission are included — built to ACPE Standards 2.0.
  • 24 specialty bundles — 135+ courses, 250+ contact hours available
  • Compliance, GLP-1, Women's Health, Behavioral Health, Specialty Pharmacy, Nursing Pharmacology, and more
  • Annual or multi-year flat-fee licensing
  • 50/50 revenue share on à la carte non-subscriber purchases
  • Author credit line required
  • Annual content updates included
Custom Development
Your topic. Our expertise. Your ACPE number.
Have a CE topic your audience needs but your team doesn't have the clinical pharmacy expertise to develop? We build the full course from scratch — you accredit it.
  • Topic scoping and learning objective development
  • Full literature review and evidence-based content development
  • Complete course package: slides, syllabus, assessments
  • Peer review and author documentation
  • Any CE format: knowledge-based, practice-based, application
  • Flat-fee per course project pricing
CE Consulting
Expert advisory for CE programs and strategy.
Need a licensed PharmD with deep CE expertise for peer review, advisory board participation, content accuracy audits, or CE program strategy? Available for hourly or retainer engagements — platforms of any size, any healthcare profession.
  • Subject matter expert peer review services
  • CE curriculum gap analysis and catalog planning
  • Content advisory and clinical accuracy review
  • ACPE submission documentation consulting
  • Hourly or project-based retainer models
  • Available for CE platforms serving any healthcare profession
Licensing Tiers
Flat annual fees by commitment length. Pricing shared after discovery call — no surprises.
1-Year License
Proposal-Based
per bundle · exact pricing after discovery call
  • Full course bundle (slides, syllabus, assessments)
  • White-label delivery under your brand
  • ACPE submission documentation
  • Author credit in submission records
  • 1 content update cycle included
Request Pricing
3-Year License
Proposal-Based
per bundle · exact pricing after discovery call
  • Everything in 2-Year
  • Full catalog access — all bundles
  • All future courses included at no extra cost
  • Custom development discount
  • Dedicated account contact
Request Pricing
Premium Add-On
In Development
Podcast CE
Audio-only narrated versions of any licensed course. Providers earn CE on the go — downloadable audio files delivered as ACPE home study activities.
Add-On
Per-course fee · any bundle
Premium Add-On
In Development
Webcast CE
Narrated slide presentations — synchronized audio with visual slides. The closest experience to a live lecture, available on-demand as video for ACPE home study.
Add-On
Per-course fee · any bundle
The Licensing Process

From first call
to live CE content — fast

Five steps from signed agreement to a fully ACPE-submission-ready course package in your hands — typically in under a week.

1
Discovery Call
20 minutes to understand your catalog gaps, audience, and CE format requirements.
2
Licensing Proposal
You receive a tailored proposal with course specs, pricing tiers, a sample deliverable, and the licensing agreement template.
3
Agreement Signed
Simple, straightforward licensing agreement. No per-learner royalties, no usage caps, no surprises.
4
Content Delivered
Full course package delivered within 5 business days — slides, syllabus, assessments, answer keys, peer review documentation, and learning objectives.
5
You Accredit & Launch
Submit under your ACPE provider number, brand it as your own, and publish to your platform. We stay behind the scenes.
About

Elevating Healthcare,
One CE at a Time

Every course is developed by a licensed, practicing clinician expert whose clinical expertise translates across nursing, advanced practice, pharmacy, and physician CE.

Scott Angus, PharmD, RPh
Scott Angus
PharmD, RPh · CE Content Author
Founder, eCEcredits.com
Follow on LinkedIn
Degree
Doctor of Pharmacy (PharmD)
License
Registered Pharmacist (RPh) · NJ License #28RI03338400 · Active
Specialty
Pharmacy law & compliance, pharmacotherapy, pharmacy benefit management, clinical analytics, clinical operations · Practice settings: retail, mail order (PIC), LTC
CE Role
CE content author & peer reviewer
Platform
eCEcredits.com — CE content development & licensing
"Built by a clinician, grounded in evidence, designed to be clear, concise, professional, and worth your time."
I started eCEcredits to help CE platforms deliver the kind of content providers actually look forward to completing. Healthcare providers want CE that's clear, concise, professional, and genuinely useful — and platforms need fresh, high-quality courses to keep their catalogs competitive. That's exactly what we build.
Education runs in my family. Both of my parents are teachers, and my twin sister followed the same path. Growing up in a household where the value of good teaching was modeled every day gave me a deep appreciation for what it actually means to help people learn — and a low tolerance for content that wastes someone's time. That same standard drives every course I develop.
Every course starts with a clinical question: what does this provider genuinely need to know to deliver better patient care? The accreditation compliance is built in from the start — so whether your platform serves Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Pharmacy Technicians, or Physicians, our content submits without friction.
I'm available as a content author, subject matter expert, and CE program advisor. If you need pharmacy CE content that passes clinical scrutiny — not just compliance review — let's talk.
Coursework
135+ Complete CE Courses Developed
Contact Hours
250+ CH Available for Licensing
Designation
IPCE Activities — RPh, PharmD, CPhT, RN, NP, PA, MD
Expertise
Law, Compliance, Clinical Pharmacology
Background

Credentials & Background

All CE content is authored to primary source standards — FDA prescribing information, published society guidelines, and peer-reviewed clinical data. Never summarized from summaries.

Licensure
PharmD · RPh (Active)
Doctor of Pharmacy degree with active Registered Pharmacist license (NJ #28RI03338400). Clinical practice across retail, mail order, long-term care, PBM, and clinical analytics.
Clinical Practice
Decades of Pharmacy Practice
Practice settings span retail, long-term care, mail order, PBM, and clinical analytics. Served as Pharmacist in Charge at a startup specialized mail order pharmacy — responsible for all clinical, regulatory, and operational oversight from launch. Every course setting gets content grounded in how that practice actually works.
IPCE Content Authorship
Core Specialty Areas
Compliance & DEA MATE Act / SUD GLP-1 / Obesity Women's Health Behavioral Health Precision Medicine
Standards
ACPE Standards 2.0
All courses built to ACPE Standards 2.0 — outcomes-based learning objectives with action verbs, IPCE activity type designation, and pre/post assessment aligned to stated objectives.
Regulatory Breadth
Multi-State Pharmacy Law Examinations — 14 States
Passed pharmacy jurisprudence examinations in 14 states — each requiring mastery of state-specific controlled substance statutes, DEA regulations, prescribing authority rules, and pharmacy practice act requirements. This cross-jurisdictional regulatory background is directly reflected in the depth and accuracy of every compliance, DEA, and MATE Act CE course in the catalog.
Source Standards
Built to Primary Source Standards
Every clinical claim traces to a primary source: FDA prescribing information, published society clinical guidelines (ADA, AHA/ACC, IDSA, ACOG, APA, ASHP, and others), or landmark trial data. Speaker notes carry inline citations on every content slide — the clinical audit trail is built in, not added at the end.
Ready to talk? Reach out directly.
Questions about licensing, content specs, or custom development — call, text, or email.
(619) 800-2153
Schedule a Discovery Call

Let's talk about
your CE catalog.

Book a 20-minute discovery call. No pitch — just a conversation about your content needs.

(619) 800-2153
Schedule a
Discovery Call
No obligation. Just a conversation about how we can fill your CE catalog gaps.
What we'll cover
Your current catalog, audience demographics, ACPE submission process, and which of our courses are the best fit.
What you'll receive after
A tailored licensing proposal with course specs, pricing tiers, a sample deliverable, and the licensing agreement template.
How fast can we move?
Signed agreement to full course file delivery in under 5 business days. ACPE submission timeline depends on your organization.
Book a Call
20-Minute Discovery Call
Select a time that works for you — calendar confirmation sent instantly.
Loading calendar...
Scheduling powered by Calendly  ·  All times shown in your local timezone
Don't see a time that works?  Call or text (619) 800-2153  or  email directly — we'll find a time.
Before the call

Help us prepare for your call — takes 60 seconds.

We'll review your answers before we talk and come prepared with the right bundles for your audience.

Which bundles interest you most?

No obligation. Scott Angus, PharmD, RPh will review personally before the call.

Request received!
We'll be in touch within one business day
to schedule your discovery call.
What happens next
Scott Angus, PharmD, RPh will personally review your request and reach out to schedule a 20-minute discovery call. No pricing, no pressure — just a conversation about your CE catalog needs.
←  Back to Home
Bundles 01 & 01b · Compliance + SUD
Compliance & Regulatory Bundle
13.0 CH Total Bundle 01: 5.0 CH Bundle 01b: 8.0 CH 8 Courses Includes Law CE IPCE Activity
Pharmacy Law Update 2026
Annual pharmacy law and regulatory update covering federal and state legislative changes, DEA regulatory actions, HIPAA updates, scope of practice expansions, and emerging compliance requirements for 2026.
1.0 CH Law Designation IPCE
1.0 CH
CS Dispensing Law & DEA Compliance
Deep-dive into controlled substance dispensing regulations, DEA Schedule requirements, pharmacy DEA registration, recordkeeping obligations, red flag recognition, and compliance audit preparation. Essential for any pharmacy practice setting.
2.0 CH Law Designation IPCE
2.0 CH
Opioid Use Disorder & Pain Management
A comprehensive review of opioid pharmacology, OUD pathophysiology, MOUD (methadone, buprenorphine, naltrexone), and evidence-based pain management strategies. Includes current CDC guidelines and state-level prescribing regulations.
2.0 CH Law 0.5 CH IPCE High Demand
2.0 CH
The Neuroscience of Addiction: Moving Beyond Stigma
Evidence-based review of addiction as a brain disease — dopaminergic pathways, neuroplasticity, and the science behind why substance use disorders develop. Designed to shift clinical perspective from moral failure to medical condition.
2.0 CHIPCE
2.0 CH
Opioid Overdose Prevention & Naloxone Distribution
Pharmacology and clinical use of naloxone across all formulations, overdose recognition, community distribution programs, and current state standing order laws. Practical and actionable for any clinical setting.
1.5 CHIPCEHigh Demand
1.5 CH
Medications for Opioid Use Disorder (MOUD): Clinical Essentials
Comprehensive review of buprenorphine, methadone, and naltrexone for OUD — mechanisms, formulations, dosing, patient selection, monitoring, and evidence base. Aligned with current SAMHSA and ASAM guidelines.
2.0 CHIPCE
2.0 CH
The MATE Act & Buprenorphine Prescribing
Covers the Mainstreaming Addiction Treatment (MATE) Act requirements, DEA registration changes, 8-hour training mandate, and the current buprenorphine prescribing landscape. Includes practical workflow guidance for implementing MOUD in practice.
1.5 CHLaw DesignationIPCE
1.5 CH
Stimulant & Alcohol Use Disorders: Pharmacotherapy Update
Current evidence and clinical approach for stimulant use disorder and alcohol use disorder — approved pharmacotherapy options, emerging treatments, and counseling strategies for the interprofessional team.
1.0 CHIPCE
1.0 CH
Bundle 01b · Compliance & SUD
MATE Act & Substance Use Disorders
8.0 Contact Hours 5 Courses Includes Law CE IPCE Activity
The Neuroscience of Addiction: Moving Beyond Stigma
Evidence-based review of addiction as a brain disease — dopaminergic pathways, neuroplasticity, and the science behind why substance use disorders develop. Designed to shift clinical perspective from moral failure to medical condition.
2.0 CHIPCE
2.0 CH
Opioid Overdose Prevention & Naloxone Distribution
Pharmacology and clinical use of naloxone across all formulations, overdose recognition, community distribution programs, and current state standing order laws. Practical and actionable for any clinical setting.
1.5 CHIPCEHigh Demand
1.5 CH
Medications for Opioid Use Disorder (MOUD): Clinical Essentials
Comprehensive review of buprenorphine, methadone, and naltrexone for OUD — mechanisms, formulations, dosing, patient selection, monitoring, and evidence base. Aligned with current SAMHSA and ASAM guidelines.
2.0 CHIPCE
2.0 CH
The MATE Act & Buprenorphine Prescribing
Covers the Mainstreaming Addiction Treatment (MATE) Act requirements, DEA registration changes, 8-hour training mandate, and the current buprenorphine prescribing landscape. Includes practical workflow guidance for implementing MOUD in practice.
1.5 CHLaw DesignationIPCE
1.5 CH
Stimulant & Alcohol Use Disorders: Pharmacotherapy Update
Current evidence and clinical approach for stimulant use disorder and alcohol use disorder — approved pharmacotherapy options, emerging treatments, and counseling strategies for the interprofessional team.
1.0 CHIPCE
1.0 CH
Bundle 02 · Clinical · Core + Extended
GLP-1 Clinical Bundle
9.0 CH Total Core 4.0 CH Extended 5.0 CH 6 Courses IPCE Activity
GLP-1 Receptor Agonists: Mechanisms, Agents & Clinical Use
Comprehensive review of GLP-1 receptor agonist pharmacology, mechanism of action, approved indications, comparative efficacy data, dosing strategies, and safety considerations for semaglutide, tirzepatide, liraglutide, and the broader class.
2.0 CHIPCETop Market Demand
2.0 CH
Optimizing GLP-1 Therapy: Titration, Side Effects & Patient Counseling
Practical application of GLP-1 therapy management: dose titration schedules, gastrointestinal side effect management, injection technique counseling, adherence strategies, and when to escalate or discontinue.
1.0 CHIPCE
1.0 CH
GLP-1 in Obesity Management
Focused review of GLP-1 agents specifically in chronic weight management — patient selection, obesity guideline alignment, realistic outcome expectations, drug shortages and access considerations, and counseling best practices.
1.0 CHIPCE
1.0 CH
Beyond Weight Loss: CV & Renal Benefits of Incretin Mimetics
Cardiovascular and renal outcome trials for GLP-1 RAs — LEADER, SUSTAIN-6, REWIND, SELECT — and clinical application of CV/renal risk reduction in patients with and without diabetes.
2.0 CHIPCE
2.0 CH
Managing Sarcopenia & Body Composition on GLP-1 Therapy
Addresses the emerging concern of lean mass loss during GLP-1 therapy — evidence on sarcopenia risk, resistance training integration, protein intake optimization, and monitoring protocols for long-term GLP-1 users.
1.5 CHIPCE
1.5 CH
The PBM Perspective: Prior Auth & Formulary Tiers for Obesity Pharmacotherapy
How pharmacy benefit managers approach obesity drug coverage — prior authorization criteria, formulary tier placement, step therapy requirements, appeals strategies, and optimizing access to GLP-1 agents across commercial and Medicare Part D plans.
1.5 CHIPCE
1.5 CH
Bundle 07 · Men's Health
Men's Health Bundle
12.0 CH6 CoursesIPCE Activity
BPH & Erectile Dysfunction
Comprehensive review of benign prostatic hyperplasia pathophysiology, alpha-1 blockers, 5-alpha reductase inhibitors, PDE5 inhibitors for ED, and combination therapy considerations. Includes counseling pearls and drug interaction management.
2.0 CHIPCE
2.0 CH
Testosterone Deficiency & Androgen Replacement
Evidence-based evaluation of hypogonadism, testosterone replacement therapy indications, formulations (gels, injections, patches, pellets), monitoring parameters, cardiovascular risk considerations, and FDA risk communication requirements.
2.0 CHIPCE
2.0 CH
Prostate Cancer: Pharmacotherapy
Comprehensive pharmacotherapy review for prostate cancer including androgen deprivation therapy (ADT), LHRH agonists/antagonists, enzalutamide, abiraterone, docetaxel, and emerging therapies. Includes side effect management and patient counseling.
2.0 CHIPCE
2.0 CH
Male Infertility & Reproductive Pharmacology
Drug-induced causes of male infertility, hormonal therapies (clomiphene, gonadotropins), varicocele treatment, and pharmacist's role in reproductive counseling. Includes medication review for reproductive impact.
2.0 CHIPCE
2.0 CH
Cardiovascular Risk in Men: Lipids, HTN & Metabolic Syndrome
Sex-specific cardiovascular risk factors in men, metabolic syndrome diagnosis and treatment, statin selection, antihypertensive therapy optimization, and lifestyle-pharmacotherapy integration for primary prevention.
2.0 CHIPCE
2.0 CH
Mental Health & Substance Use in Men
Depression, anxiety, and substance use disorders with male-specific presentation patterns. Pharmacotherapy options, barriers to care, and clinical communication strategies for engaging male patients in mental health treatment.
2.0 CHIPCE
2.0 CH
Bundle 13 · Herbal & Alt Medicine
Herbal & Integrative Medicine Bundle
9.0 CH5 CoursesIPCE Activity
Supplement Regulation, Quality & Labeling
FDA regulatory framework for dietary supplements under DSHEA, GMP requirements, USP verification, third-party testing, label claim limitations, and practitioner guidance for evaluating product quality.
1.5 CHIPCE
1.5 CH
Herb-Drug Interactions: Clinical Foundations
Pharmacokinetic and pharmacodynamic herb-drug interactions for the most clinically significant botanical agents including St. John's wort, ginkgo, garlic, ginger, valerian, and echinacea. Evidence grading and clinical decision-making framework.
2.0 CHIPCEHigh Demand
2.0 CH
Cannabis & Cannabinoids in Clinical Practice
Endocannabinoid system pharmacology, CBD vs. THC clinical applications, FDA-approved cannabinoid products (Epidiolex, dronabinol, nabilone), state medical cannabis programs, and evidence-based counseling for patients.
2.0 CHIPCE
2.0 CH
Melatonin, Adaptogens & Sleep Supplements
Evidence review for melatonin dosing and formulations, ashwagandha, rhodiola, and magnesium for sleep and stress. Compares supplement evidence to FDA-approved sleep pharmacotherapy and appropriate patient selection.
1.5 CHIPCE
1.5 CH
Integrative Oncology: Supplements in Cancer Care
Evidence-based review of supplement use in cancer patients — antioxidants during chemotherapy, mistletoe, mushroom extracts, and interactions with oncology medications. Risk stratification and communication with oncology teams.
2.0 CHIPCE
2.0 CH
Bundle 14 · OTC Pharmacology
OTC Pharmacology Bundle
7.5 CH4 CoursesIPCE Activity
OTC Analgesics: Safe Use & Counseling
Acetaminophen hepatotoxicity risk stratification, NSAID cardiovascular and GI safety, aspirin for pain vs. cardiovascular prevention, combination analgesic products, and special population counseling (pediatrics, pregnancy, renal/hepatic impairment).
2.0 CHIPCE
2.0 CH
OTC Allergy & Antihistamines
First- vs. second-generation antihistamine comparison, intranasal corticosteroids, decongestants and pseudoephedrine regulations, ocular allergy products, and allergy immunotherapy adjuncts available OTC.
1.5 CHIPCE
1.5 CH
Self-Care Triage: Refer vs. Recommend
Structured clinical decision-making framework for OTC product recommendation vs. referral to care. Covers GI conditions (GERD, IBS, constipation, diarrhea), cold/flu, dermatologic conditions, and minor wound care.
2.0 CHIPCEHigh Demand
2.0 CH
OTC Cough, Cold & Sleep Products
Dextromethorphan, guaifenesin, and combination cold products — evidence, misuse risks, and pediatric safety. OTC sleep aids (diphenhydramine, doxylamine), melatonin, and the emerging role of low-dose doxepin.
2.0 CHIPCE
2.0 CH
Bundle 16 · Hospital Pharmacy
Hospital Pharmacy Bundle
12.0 CH6 CoursesIPCE Activity
Antimicrobial Stewardship in the Hospital
Core principles of antimicrobial stewardship programs (ASPs), antibiotic selection, de-escalation strategies, PK/PD optimization, culture-guided therapy, and measurement of stewardship outcomes. Aligned with IDSA/SHEA guidelines.
2.0 CHIPCE
2.0 CH
High-Alert Medications in the Hospital
ISMP high-alert medication list, error prevention strategies, safe use of anticoagulants, concentrated electrolytes, insulin, opioids, and chemotherapy in inpatient settings. Includes CPOE and smart pump safety.
2.0 CHIPCE
2.0 CH
Emergency Pharmacotherapy: Code Blue
ACLS pharmacology — epinephrine, amiodarone, vasopressin, atropine, adenosine, and magnesium in cardiac arrest and arrhythmia management. Rapid sequence intubation medications and post-resuscitation care.
2.0 CHIPCE
2.0 CH
Critical Care Pharmacotherapy
Vasopressor and inotrope selection in septic/cardiogenic shock, sedation/analgesia/delirium (PADIS) guidelines, stress ulcer prophylaxis, DVT prevention, and nutrition support pharmacotherapy in the ICU.
2.0 CHIPCE
2.0 CH
IV Compatibility, Stability & Compounding
IV admixture compatibility assessment, USP 795/797/800 compounding standards, HEPA filtration and ISO classifications, BUD dating, and pharmacist liability in hospital compounding.
2.0 CHIPCE
2.0 CH
Transitions of Care: Hospital to Home
Medication reconciliation best practices, high-risk medications at discharge, collaborative prescribing, HEDIS measures, readmission reduction strategies, and pharmacist roles in care transitions and MTM.
2.0 CHIPCE
2.0 CH
Bundle 17 · Informatics & Data Analytics
Informatics & Data Analytics Bundle
21.0 CH12 CoursesIPCE Activity
Healthcare Informatics Foundations
EHR architecture, HL7 FHIR standards, interoperability frameworks, clinical decision support (CDS) systems, and the pharmacist's role in health information technology governance and implementation.
2.0 CHIPCE
2.0 CH
Population Health Analytics in Pharmacy
Risk stratification models, population-level medication adherence metrics, predictive analytics for high-risk patients, quality measure reporting (STAR ratings, HEDIS), and pharmacy dashboard interpretation.
2.0 CHIPCE
2.0 CH
Pharmacy Claims Data: BIN, PCN & Adjudication
PBM claims processing, BIN/PCN/Group number structure, DAW codes, adjudication logic, formulary tier construction, and prior authorization workflows. Essential for pharmacy benefit and managed care roles.
2.0 CHIPCE
2.0 CH
Real-World Evidence & Pharmacoepidemiology
RWE study designs, administrative database analysis, confounding and bias in observational studies, FDA RWE framework, and application of pharmacoepidemiology to drug safety and effectiveness decisions.
2.0 CHIPCE
2.0 CH
AI & Machine Learning in Pharmacy Practice
Clinical applications of AI in pharmacy: drug interaction detection, dosing optimization, readmission prediction, natural language processing in clinical notes, and ethical considerations in algorithmic decision-making.
2.0 CHIPCE
2.0 CH
Pharmacy Quality Metrics & Star Ratings
CMS Part D Star Ratings structure, MTM eligibility and documentation, CMR and TMR workflow, medication adherence measures (PDC), and pharmacy performance contracting in value-based care.
1.5 CHIPCE
1.5 CH
Health Data Privacy: HIPAA & Cybersecurity
HIPAA Privacy and Security Rule requirements for pharmacy and health data, PHI definitions, minimum necessary standard, breach notification, ransomware and phishing in healthcare settings, and workforce training obligations for covered entities and business associates.
1.5 CHIPCE
1.5 CH
Health Information Exchange & Interoperability
HIE network types (centralized, federated, hybrid), FHIR API implementation, CommonWell and Carequality frameworks, patient matching challenges, medication history accuracy from HIE sources, and pharmacist use cases for accessing external patient data.
1.5 CHIPCE
1.5 CH
Clinical Decision Support: Design & Implementation
CDS hook types (alerts, order sets, documentation templates), alert fatigue causes and mitigation strategies, evidence-based CDS design, pharmacist-led CDS governance, drug interaction alert optimization, and measuring CDS effectiveness in reducing medication errors.
2.0 CHIPCE
2.0 CH
Telepharmacy Technology & Remote Verification
Remote dispensing unit (RDU) technology, video verification workflows, central fill operations, state telepharmacy licensure requirements, quality assurance in remote settings, and NABP e-Profile integration for telepharmacy credentialing.
1.5 CHIPCE
1.5 CH
Natural Language Processing in Clinical Documentation
NLP fundamentals, named entity recognition for drug names and diagnoses, de-identification of clinical notes, extraction of medication regimen data from unstructured text, and practical applications in adverse drug event detection and pharmacovigilance.
1.5 CHIPCE
1.5 CH
Digital Health Regulation: FDA, CMS & App Oversight
FDA Digital Health Center of Excellence framework, Software as a Medical Device (SaMD) classification, FDA-authorized digital therapeutics (DTx), CMS coverage of remote patient monitoring (RPM), and pharmacist scope in digital health program management.
1.5 CHIPCE
1.5 CH
Bundle 18 · Long-Term Care (LTC)
Long-Term Care Bundle
11.5 CH6 CoursesIPCE Activity
Medication Regimen Review: Federal Requirements
CMS Conditions of Participation for LTC pharmacist services, MRR documentation standards, F758/F757 tags, Unnecessary Drug criteria, and pharmacist consultant roles in SNF quality improvement.
2.0 CHIPCE
2.0 CH
Psychotropic Medication Use in LTC
CMS antipsychotic reduction initiative, OBRA-87 guidelines, appropriate use of antidepressants and anxiolytics in dementia, non-pharmacological approaches, and documentation requirements for PRN psychotropic use.
2.0 CHIPCE
2.0 CH
End-of-Life & Palliative Pharmacotherapy
Symptom management at end of life — pain, dyspnea, secretions, agitation. Opioid rotation, comfort-focused prescribing, hospice eligibility criteria, and pharmacist communication in goals-of-care conversations.
2.0 CHIPCE
2.0 CH
Deprescribing in the Elderly
Beers Criteria 2023 updates, STOPP/START criteria, polypharmacy burden assessment, deprescribing protocols for PPIs, benzodiazepines, antihypertensives, and statins in frail older adults.
2.0 CHIPCEHigh Demand
2.0 CH
Wound Care & Infection Management in LTC
Pressure injury classification, antimicrobial selection for skin/soft tissue infections in LTC, MRSA colonization management, antibiotic stewardship in the post-acute setting, and infection control documentation.
1.5 CHIPCE
1.5 CH
Falls, Fractures & High-Risk Medications
Medication-associated fall risk (Beers high-risk meds, antihypertensives, psychotropics), vitamin D and calcium evidence, osteoporosis pharmacotherapy in LTC, and QAPI fall reduction program design.
2.0 CHIPCE
2.0 CH
Bundle 19 · Mail Order & Specialty Dist.
Mail Order & Specialty Distribution Bundle
10.5 CH6 CoursesIPCE Activity
Mail Order Operations: Regulatory Framework
State reciprocity, NABP e-Profile, DEA registration for mail order, 90-day supply regulations, out-of-state dispensing requirements, and URAC accreditation standards for mail service pharmacy.
1.5 CHIPCE
1.5 CH
Specialty Pharmacy Distribution: REMS & Hub Services
REMS program structure and pharmacist obligations, limited distribution drug (LDD) networks, specialty pharmacy accreditation (URAC, ACHC), hub services model, and prior authorization support.
2.0 CHIPCE
2.0 CH
Telepharmacy & Remote Dispensing
Telepharmacy models (central fill, remote dispensing units, video verification), state licensure requirements, CMS billing considerations, and quality assurance in remote pharmacist verification.
1.5 CHIPCE
1.5 CH
Cold Chain Management & Temperature Excursions
USP 1079 storage and distribution guidelines, WHO PQS cold chain standards, temperature mapping, excursion documentation, biologics and vaccine stability data, and carrier/shipper qualification.
2.0 CHIPCE
2.0 CH
Pharmacy Benefit Management: PBM Operations
PBM contracting, network pharmacy agreements, MAC pricing and appeals, formulary management, DIR fees, spread pricing transparency, and the evolving regulatory landscape post-IRA.
2.0 CHIPCE
2.0 CH
340B Program Compliance
340B drug pricing program eligibility, covered entity obligations, contract pharmacy arrangements, duplicate discount prevention, HRSA audit findings, and emerging 340B legislative changes.
1.5 CHIPCE
1.5 CH
Bundle 15 · Dermatology
Dermatology Bundle
8.0 CH4 CoursesIPCE Activity
Topical Corticosteroids: Clinical Mastery
Potency classification, vehicle selection, appropriate use duration, systemic absorption concerns, tachyphylaxis, and counseling on application technique. Includes comparative evidence across dermatologic conditions.
2.0 CHIPCE
2.0 CH
Atopic Dermatitis: Pharmacotherapy Update
Evidence-based review of atopic dermatitis treatment ladder — emollients, topical calcineurin inhibitors, dupilumab, tralokinumab, JAK inhibitors (upadacitinib, abrocitinib), and practical patient counseling.
2.0 CHIPCEHigh Demand
2.0 CH
Acne Vulgaris: Comprehensive Pharmacotherapy
Topical retinoids, benzoyl peroxide, antibiotics, dapsone, combined hormonal contraceptives for acne, and isotretinoin iPLEDGE program requirements. Includes stepwise approach and resistance considerations.
2.0 CHIPCE
2.0 CH
Psoriasis: Biologics & Small Molecules
Psoriasis pathophysiology, TNF-alpha inhibitors, IL-17, IL-23 and IL-12/23 inhibitors, PDE4 inhibitors (apremilast), TYK2 inhibitors (deucravacitinib), and pharmacist monitoring protocols for biologic therapy.
2.0 CHIPCE
2.0 CH
Bundle 02b · Clinical · Extended Tier
GLP-1 Extended Bundle
5.0 CH3 CoursesAdd-on to CoreIPCE Activity
Beyond Weight Loss: CV & Renal Benefits of Incretin Mimetics
Review of LEADER, SUSTAIN-6, PIONEER-6, AMPLITUDE-O, and SELECT trial data on cardiovascular outcomes. Kidney protection evidence (FLOW trial, semaglutide for CKD), and how to counsel patients on benefits beyond glycemic control.
2.0 CHIPCE
2.0 CH
Managing Sarcopenia & Body Composition on GLP-1 Therapy
Skeletal muscle loss risk with rapid weight reduction, resistance training recommendations, dietary protein optimization, emerging data on muscle-sparing GLP-1 effects, and monitoring strategies for lean mass preservation.
1.5 CHIPCE
1.5 CH
The PBM Perspective: Prior Auth & Formulary Tiers for Obesity
Step therapy requirements, prior authorization criteria for semaglutide and tirzepatide, formulary exclusion landscape, appeals strategy, coverage gap navigation, and the pharmacist's role in access advocacy.
1.5 CHIPCE
1.5 CH
Bundle 03 · Cardiometabolic
Cardiometabolic Bundle
5.0 CH3 CoursesIPCE Activity
SGLT2 Inhibitors: Beyond Diabetes
Comprehensive review of SGLT2 inhibitor pharmacology, FDA-approved indications across diabetes, heart failure (HFrEF and HFpEF), and CKD. Covers comparative efficacy, mechanism of cardiorenal protection, contraindications, and patient counseling on DKA risk and genital infections.
2.0 CHIPCEHigh Demand
2.0 CH
SGLT2 in Heart Failure & CKD
Focused review of DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, CREDENCE, and DAPA-CKD trial outcomes. Practical guidance on initiating SGLT2 inhibitors in non-diabetic heart failure and CKD patients, including eGFR thresholds and monitoring.
1.0 CHIPCE
1.0 CH
Diabetes Technology & CGM
Continuous glucose monitoring (CGM) systems, ambulatory glucose profiles (AGP), time-in-range targets, insulin pump therapy, closed-loop systems, and the pharmacist role in diabetes technology counseling and data interpretation.
2.0 CHIPCE
2.0 CH
Bundle 04 · Neurodegenerative
Neurodegenerative Disease Bundle
12.0 CH6 CoursesCore 6.0 CHExtended 6.0 CHIPCE Activity
Alzheimer's: Anti-Amyloid Therapies
Mechanism of amyloid-beta accumulation, FDA approval pathway for lecanemab (Leqembi) and donanemab, ARIA monitoring protocols, patient selection criteria, infusion center requirements, and counseling families on realistic expectations.
2.0 CHIPCEHigh Demand
2.0 CH
Parkinson's Disease Pharmacotherapy
Dopaminergic pharmacology, levodopa/carbidopa formulations, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, and device-aided therapies. Motor fluctuation management, wearing-off, dyskinesia, and non-motor symptom treatment.
2.0 CHIPCE
2.0 CH
Neuropsychiatry in Dementia
BPSD (behavioral and psychological symptoms of dementia) management — agitation, psychosis, depression, and sleep disturbances. Evidence for antipsychotics, SSRIs, citalopram, valbenazine, brexpiprazole (Rexulti for agitation in Alzheimer), and non-pharmacological approaches.
2.0 CHIPCE
2.0 CH
Multiple Sclerosis: Disease-Modifying Therapies
MS pathophysiology, treatment algorithm from platform therapies to high-efficacy DMTs. Comparative review of interferons, glatiramer, natalizumab, ocrelizumab, ofatumumab, siponimod, cladribine, and ozanimod. REMS considerations and monitoring.
2.0 CHIPCE
2.0 CH
Seizure & Epilepsy Management
Seizure classification (ILAE 2017), AED selection by seizure type, drug interactions with enzyme-inducing AEDs, newer agents (brivaracetam, cenobamate, fenfluramine), status epilepticus treatment, and women with epilepsy considerations.
2.0 CHIPCE
2.0 CH
Migraine & CGRP Inhibitors
Migraine pathophysiology, acute treatment (triptans, gepants, ditans), preventive therapy (CGRP monoclonal antibodies: erenumab, fremanezumab, galcanezumab, eptinezumab), oral gepants for prevention (atogepant, rimegepant), and medication overuse headache.
2.0 CHIPCE
2.0 CH
Bundle 05 · Geriatric
Geriatric Pharmacotherapy Bundle
3.0 CH2 CoursesIPCE Activity
Polypharmacy & Deprescribing
Polypharmacy burden in older adults, Beers Criteria 2023 and STOPP/START v3 updates, structured deprescribing frameworks for PPIs, benzodiazepines, antihypertensives, statins, and anticholinergics. Practical tools for medication burden assessment and patient communication.
2.0 CHIPCEHigh Demand
2.0 CH
Falls Prevention & Medication Safety
Medication classes contributing to fall risk, STOPP fall-risk medications, vitamin D and calcium evidence revisited, osteoporosis pharmacotherapy selection in frail patients, and multidisciplinary fall prevention program design.
1.0 CHIPCE
1.0 CH
Bundle 06 · Nursing Pharmacology
Nursing Pharmacology Bundle
12.0 CH6 CoursesCore 6.0 CHExtended 6.0 CHRN · LPN · NP
Medication Safety: Rights, Errors & Near-Misses
The 10 rights of medication administration, ISMP high-alert medications for nurses, error reporting systems (MERP), just culture principles, barcode medication administration (BCMA), and smart pump safety features. Case-based learning approach.
2.0 CHIPCE
2.0 CH
Pain Management: Opioids, Adjuvants & Multimodal Analgesia
Opioid pharmacology and equianalgesic dosing, PCA safety, non-opioid adjuvants (NSAIDs, acetaminophen, gabapentinoids, ketamine), multimodal analgesia protocols, and nursing assessment of pain, sedation, and respiratory depression.
2.0 CHIPCE
2.0 CH
IV Medication Administration & Compatibility
IV access types, infusion rate calculations, osmolarity and peripheral vs central line requirements, high-risk IV medications (potassium, heparin, insulin, vasoactives), compatibility resources, and ISMP recommendations for IV safety.
2.0 CHIPCE
2.0 CH
Pharmacology Update 2026: Key Drug Classes for Nurses
Annual update on FDA drug approvals and label changes most relevant to nursing practice — new antibiotics, biologics, oncology agents, and cardiovascular drugs. Focuses on nursing administration, monitoring, and patient education considerations.
2.0 CHIPCE
2.0 CH
Anticoagulation Therapy: Nursing Management
Heparin, LMWH, warfarin, and DOAC pharmacology and monitoring. Nursing assessment for bleeding, bridging therapy, reversal agents (protamine, phytonadione, idarucizumab, andexanet), and patient discharge counseling.
2.0 CHIPCE
2.0 CH
Diabetes Pharmacotherapy for Nurses
Insulin types, concentration, and administration technique. Oral antidiabetic agents by class, hypoglycemia recognition and treatment, sick-day rules, and nursing management of DKA and HHS. CGM basics and interpreting glucose values.
2.0 CHIPCE
2.0 CH
Bundle 07 · Women's Health
Women's Health Bundle
9.0 CH5 CoursesIPCE Activity
Maternal & Reproductive Pharmacotherapy
Medication safety in pregnancy and lactation — FDA labeling framework, LactMed, TIS resources. High-risk drug categories (SSRIs, antiepileptics, biologics), gestational diabetes management, hypertensive disorders of pregnancy, and peripartum depression treatment.
2.0 CHIPCE
2.0 CH
Contraception & Hormone Therapy
Combined and progestin-only contraceptives, IUDs, implants, emergency contraception, and drug interactions. Hormone therapy for menopausal symptoms — WHI trial reinterpretation, current NAMS guidelines, product selection, and individualized risk assessment.
2.0 CHIPCE
2.0 CH
Menopause Management & Emerging Agents
Vasomotor symptom treatment including fezolinetant (Veozah) — the first non-hormonal neurokinin B antagonist. GSM pharmacotherapy, testosterone for HSDD, bioidentical vs FDA-approved HRT, and bone health considerations in perimenopause.
2.0 CHIPCEHigh Demand
2.0 CH
Osteoporosis: Pharmacotherapy Update
DEXA interpretation, FRAX tool, bisphosphonate selection and monitoring, denosumab discontinuation syndrome, anabolic agents (teriparatide, abaloparatide, romosozumab), and sequential therapy rationale.
1.5 CHIPCE
1.5 CH
PCOS & Endocrine Disorders in Women
PCOS diagnostic criteria (Rotterdam), metformin and hormonal therapy in PCOS, inositol evidence, endometriosis pharmacotherapy (dienogest, elagolix, relugolix), and thyroid disorders in women of reproductive age.
1.5 CHIPCE
1.5 CH
Bundle 08 · Precision Medicine
Precision Medicine Bundle
4.0 CH2 CoursesIPCE Activity
Pharmacogenomics in Practice (PGx)
PGx fundamentals — CYP enzyme phenotypes (poor/intermediate/normal/ultrarapid metabolizer), actionable gene-drug pairs (CPIC guidelines), clinical implementation of CYP2D6, CYP2C19, CYP2C9, SLCO1B1, DPYD, TPMT, and HLA-B alleles. Real-world PGx testing interpretation.
2.0 CHIPCEHigh Demand
2.0 CH
Biomarker-Guided Therapy: Oncology & Beyond
NTRK fusions, PD-L1 expression, HER2, BRCA, MSI-H/dMMR and matched targeted therapies. Liquid biopsy, ctDNA monitoring, and companion diagnostics. Pharmacist role in tumor board participation and biomarker result interpretation.
2.0 CHIPCE
2.0 CH
Bundle 09 · Infectious Disease
Infectious Disease Bundle
8.0 CH5 CoursesCore 4.0 CHExtended 4.0 CHIPCE Activity
Antibiotic Stewardship
ASP program structure, antibiotic selection principles, PK/PD optimization (time-dependent vs concentration-dependent killing), de-escalation, culture-guided therapy, duration of therapy evidence, and stewardship metrics. IDSA/SHEA 2023 guidelines aligned.
2.0 CHIPCE
2.0 CH
Immunization Update 2026
ACIP 2026 schedule updates, RSV vaccines (nirsevimab, mResvia, Abrysvo, Arexvy), updated COVID-19 vaccine recommendations, mpox vaccination, pharmacist authority to vaccinate by state, VIS requirements, and cold chain compliance.
2.0 CHIPCE
2.0 CH
HIV Prevention & Treatment: PrEP, ART & U=U
HIV life cycle and ART mechanisms, PrEP (tenofovir/emtricitabine, cabotegravir LA), ART regimen selection (DTG-based preferred), DHHS 2025 guidelines, drug interactions with ART, and treatment as prevention (U=U: Undetectable = Untransmittable).
2.0 CHIPCEHigh Demand
2.0 CH
Travel Medicine & Emerging Infections
Pre-travel vaccine assessment, malaria prophylaxis (chloroquine, atovaquone/proguanil, doxycycline), travelers diarrhea treatment, mpox, avian influenza, and pharmacist counseling for international travelers.
1.0 CHIPCE
1.0 CH
VPD Outbreaks & the Anti-Vaccine Movement
Vaccine-preventable disease resurgence (measles, whooping cough), anti-vaccine communication science, motivational interviewing techniques for vaccine hesitancy, and pharmacist role in community immunization advocacy.
1.0 CHIPCE
1.0 CH
Bundle 10 · Behavioral Health
Behavioral Health Bundle
10.5 CH7 CoursesAll ProvidersIPCE Activity
Mental Health Pharmacotherapy Essentials
Antidepressants, antipsychotics, mood stabilizers — mechanism, selection, monitoring, and switching. Evidence-based treatment algorithms for MDD, bipolar disorder, generalized anxiety, and PTSD. Focused on outpatient and collaborative care settings.
2.0 CHIPCE
2.0 CH
Esketamine, Zuranolone & the Rapid-Acting Frontier
Mechanism of rapid-acting antidepressants, esketamine (Spravato) REMS program and administration requirements, zuranolone (Zurzuvae) for MDD and PPD, and the emerging pipeline including psychedelic-assisted therapy clinical trials.
1.5 CHIPCE
1.5 CH
ADHD Pharmacotherapy Across the Lifespan
Stimulant and non-stimulant options (amphetamines, methylphenidate, viloxazine, atomoxetine, guanfacine), DEA Schedule II requirements for ADHD medications, telemedicine prescribing rules, adult ADHD diagnosis, and treatment in pregnancy.
2.0 CHIPCE
2.0 CH
Bundle 11 · Specialty Pharmacy
Specialty Pharmacy Bundle
9.0 CH5 CoursesRPh · PharmD · NPIPCE Activity
Biosimilars & Specialty Drug Management
FDA biosimilar and interchangeable designations, automatic substitution laws by state, immunogenicity considerations, switching evidence, and formulary management of biologics. Focus on adalimumab biosimilar landscape and emerging products.
2.0 CHIPCE
2.0 CH
REMS Programs: Patient Access & Pharmacist Obligations
FDA REMS framework, shared REMS programs, element-to-ensure-safe-use (ETASU) compliance, pharmacist certification requirements (iPLEDGE, REMS for clozapine, thalidomide analogs, opioids), and patient enrollment workflows.
2.0 CHIPCE
2.0 CH
Prior Authorization & Patient Access Advocacy
Prior authorization process anatomy, clinical criteria submission, peer-to-peer requests, appeal strategy, insurance denial patterns for specialty drugs, manufacturer patient assistance programs, and co-pay card regulations.
2.0 CHIPCE
2.0 CH